Nextera
Discovers TCR-like antibody drug candidates against disease-specific pHLA targets for cancer and autoimmune disease
Highlights
- New on EvolcAdded 2026-10-28
About Nextera
Nextera is a drug and target discovery company. Its NextCore platform, built on pIX phage display technology, is used to develop TCR-like antibody lead candidates that bind disease-specific pHLA targets. The stated focus areas are cancer, autoimmunity and inflammatory diseases.
Nextera's strategy is to discover new targets and develop cognate drugs together with partners, with the aim of addressing complex diseases in major indications.
The company was spun out from a Centre of Excellence research environment at the University of Oslo and Oslo University Hospital. Its registered headquarters is in Oslo, Norway. The careers page invites open applications, with no specific open roles listed.
Product: NextCore, an integrated platform for developing antibody-based drug candidates against pHLA targets, built on pIX phage display.
Jobs at Nextera
More biotech & pharma companies
Nocteva
Organoid models and drug discovery services for rare disease researchers and biotech companiesYoung companyNew on EvolcNorsk Medisinsk Syklotronsenter
Makes short-lived PET radiopharmaceuticals for diagnostic imaging, serving clinics and pharma partners from OsloNew on EvolcNuclithera
Targeted radiopharmaceuticals for patients with metastatic and difficult-to-treat cancersYoung companyNew on EvolcNykode Therapeutics
Develops immunotherapies for patients with cancer and autoimmune diseases using a modular biotech platformNew on EvolcOncosyne
Tumoroid-based drug screening and predictive diagnostics for pharmaceutical companies and cancer care providersNew on EvolcPharma Holdings
Develops intranasal antimicrobial drugs for patients with respiratory viral infectionsNew on Evolc
.png){kind=small}
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Apache
- Google Tag Manager
- WooCommerce
- WordPress
- jQuery